Phase 2 N=59 Randomized Triple-blind Prevention

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

Premature Atrial Contraction

Bottom Line

View on ClinicalTrials.gov: NCT02837328 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2019

Primary outcome: Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Oral Magnesium Supplement (Drug); Placebo (Drug)
Age: Adult, Older Adult · 55+ yrs
Sex: All
Sponsor: University of Minnesota
Primary completion: Sep 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Premature Atrial Contractions (PACs)	-0.6; -5.6	—
SECONDARY Change in Magnesium Concentration	0.07; 0	—

Summary

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

Eligibility Criteria

Inclusion Criteria

Age 55 and older
Ability to speak English
Availability to attend baseline and follow-up visit approximately 12 weeks after baseline

Exclusion Criteria

Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease
Use of type I and III antiarrhythmics or digoxin
Current use of magnesium supplements
Any prior history of allergy or intolerance to magnesium
Prior history of inflammatory bowel disease or any severe gastrointestinal disorder

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02837328). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.